Center for Biologies Evaluation Research

Congress passes the Prescription Drug User Fee Act, which requires the pharmaceutical industry to pay user fees to the FDA in return for faster approval time. With the funds, the FDA will hire new workers for the Center for Drug Evaluation and Research and the Center for Biologies Evaluation Research. 

Ellenberg SS, Center for Biologies Evaluation Research, FDA Statement (widespread)... 

Fig. 2 This figure represents the career options for individuals interested in the clinical pharmaceutical sciences. Abbreviations PhaRMA, Pharmaceutical Research Manufacturers CROs, Contract Research Organizations SMOs, Site Management Organizations NIH, National Institutes of Health CDC, Center for Disease Control and Prevention HCFA, Health Care Financing Administration FDA, Food and Drug Administration EPA, Environmental Protection Agency CDER, Center for Drug Evaluation Research CBER, Center for Biological Evaluation Research.

Center for Biologies Evaluation and Research (CBER). This center is responsible for the regulation and approval of ah biological products intended for use in the treatment, prevention, or cure of diseases or injuries to humans. A biological product is any vims, therapeutic semm, toxin, antitoxin, vaccine, blood or blood component or derivative, or analogous product (5). It also includes products produced by biotechnology, such as interferons and erythropoietins. 

Standardization and Testing". The Center for Biologies Evaluation and Research has set guidelines for the vaccine which include standards for si2e of the individual polysaccharides and specifications for both purity (absence of protein and nucleic acid) and chemical and immunological identity. 

The Center for Biologies Evaluation and Research (CBER) is responsible for the oversight of what might be considered more traditional biological products, such as... 

Once the FDA receive the initial submission, an IND reference number is assigned. The application is then passed on to the appropriate review centre either the Center for Drug Evaluation and Research (CDER), or the Center for Biologies Evaluation and Research (CBER). Various experts will then review the submitted documents, the purpose being to ensure that the safety of subjects is not compromised and, in the case of Phase II and III studies, that the quality of study design is scientifically adequate. The FDA are allowed 30 days to complete the initial review, after which the study can commence, provided that it has been approved by an Institutional Review Board (IRB). 

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologies Evaluation and Research (CBER). Guidance for Industry Population Pharmacokinetics. http //www.fda.gov/cder/guidance/1852fnl.pdf (accessed October 1,... 

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologies Evaluation and Research. 

Fig. 3 Organizational chart for the Center for Biologies Evaluation and Research.

The International Conferences on Harmonization has published its document S6, Preclincial Safety Evaluation of Biotechnology-Derived Pharmaceuticals. The FDA (the Center for Drug Evaluation and Research, and the Center for Biologies Evaluation and Research jointly) has published the document as a Guidance for Industry (Anon., 1997a, b FDA, 1989, Hayes and Reyffel, 1999). 

Buesing, Mary McSweegan. (1999). Submitting biologies applications to the center for biologies evaluation and research electronically. Drug Information J. 33 1-15. 

---